Glut1 and Glut3 expression in lymphoma and their association with tumor intensity on 18F-fluorodeoxyglucose positron emission tomography
Publication
, Journal Article
Khandani, AH; Dunphy, CH; Meteesatien, P; Dufault, DL; Ivanovic, M; Shea, TC
Published in: Nuclear Medicine Communications
August 2009
Duke Scholars
Published In
Nuclear Medicine Communications
DOI
ISSN
0143-3636
Publication Date
August 2009
Volume
30
Issue
8
Start / End Page
594 / 601
Publisher
Ovid Technologies (Wolters Kluwer Health)
Related Subject Headings
- Nuclear Medicine & Medical Imaging
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Khandani, A. H., Dunphy, C. H., Meteesatien, P., Dufault, D. L., Ivanovic, M., & Shea, T. C. (2009). Glut1 and Glut3 expression in lymphoma and their association with tumor intensity on 18F-fluorodeoxyglucose positron emission tomography. Nuclear Medicine Communications, 30(8), 594–601. https://doi.org/10.1097/mnm.0b013e32832cc295
Khandani, Amir H., Cherie H. Dunphy, Patcharica Meteesatien, Darin L. Dufault, Marija Ivanovic, and Thomas C. Shea. “Glut1 and Glut3 expression in lymphoma and their association with tumor intensity on 18F-fluorodeoxyglucose positron emission tomography.” Nuclear Medicine Communications 30, no. 8 (August 2009): 594–601. https://doi.org/10.1097/mnm.0b013e32832cc295.
Khandani AH, Dunphy CH, Meteesatien P, Dufault DL, Ivanovic M, Shea TC. Glut1 and Glut3 expression in lymphoma and their association with tumor intensity on 18F-fluorodeoxyglucose positron emission tomography. Nuclear Medicine Communications. 2009 Aug;30(8):594–601.
Khandani, Amir H., et al. “Glut1 and Glut3 expression in lymphoma and their association with tumor intensity on 18F-fluorodeoxyglucose positron emission tomography.” Nuclear Medicine Communications, vol. 30, no. 8, Ovid Technologies (Wolters Kluwer Health), Aug. 2009, pp. 594–601. Crossref, doi:10.1097/mnm.0b013e32832cc295.
Khandani AH, Dunphy CH, Meteesatien P, Dufault DL, Ivanovic M, Shea TC. Glut1 and Glut3 expression in lymphoma and their association with tumor intensity on 18F-fluorodeoxyglucose positron emission tomography. Nuclear Medicine Communications. Ovid Technologies (Wolters Kluwer Health); 2009 Aug;30(8):594–601.
Published In
Nuclear Medicine Communications
DOI
ISSN
0143-3636
Publication Date
August 2009
Volume
30
Issue
8
Start / End Page
594 / 601
Publisher
Ovid Technologies (Wolters Kluwer Health)
Related Subject Headings
- Nuclear Medicine & Medical Imaging
- 1103 Clinical Sciences